Inhibition of Histone Deacetylase Promotes a Neuroprotective Mechanism in an Experimental Model of Parkinson's Disease

Overview

Journal Arch Med Sci

Specialty General Medicine

Date 2024 May 17

PMID 38757033

Authors

Hang Li

Guolin Shi

Hao Zha

Liqing Zheng

Zhan Luo

Ying Wang

Affiliations

Soon will be listed here.

Abstract

Introduction: Therapies targeting histone deacetylase (HDAC) have gained wider attention in the treatment of various clinical conditions. However, the use of HDAC inhibitors in pre-clinical trials in the case of Parkinson's disease (PD) is very limited. In the present study, the HDAC inhibitor, entinostat, was tested in animals induced with Parkinson's disease experimentally.

Material And Methods: Wistar male rats (150 ±10 g) were administered with rotenone (2 mg/kg/day, s.c.) for 21 days to induce PD, while entinostat (20 mg/kg) was given intraperitoneally. Then, the neurological functions, PD markers, and HDACs were analysed in the control and experimental animals.

Results: The results demonstrated that rats that received entinostat displayed progressive motor, behavioural, and neurological function with attenuated α-synuclein and improved tyrosine-hydroxylase compared to control cells. Moreover, the induction of PD in rats demonstrated reduced levels of H2S, dopamine, 3, and 4-dihydroxyphenylacetic acid (DOPAC), and increased monoamine oxidase activity in PD rats. However, the rats that received entinostat demonstrated progressive levels of dopa and DOPAC, with attenuated levels of HDAC-2, -4, and -6 mRNA in the PD rats compared to controls. On the other hand, elevated ( < 0.01) levels of PD marker genes such as GDF3 and NMDA2b were reduced, with a significant increase in neuroprotective genes such as VDAC3 and CBX5 in entinostat-supplemented rats.

Conclusions: The study results suggest that inhibition of HDAC systematically improves the neurological functions, and hence treatments, emphasizing that HDACI, as the speculated mechanism, will be a promising mode of treatment in PD.

References

de Lau L, Breteler M . Epidemiology of Parkinson's disease. Lancet Neurol. 2006; 5(6):525-35. DOI: 10.1016/S1474-4422(06)70471-9. View

Rocha S, Freitas A, Guimaraes S, Vitorino R, Aroso M, Gomez-Lazaro M . Biological Implications of Differential Expression of Mitochondrial-Shaping Proteins in Parkinson's Disease. Antioxidants (Basel). 2017; 7(1). PMC: 5789311. DOI: 10.3390/antiox7010001. View

Zhu S, Denman C, Cobanoglu Z, Kiany S, Lau C, Gottschalk S . The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells. Pharm Res. 2013; 32(3):779-92. PMC: 4014531. DOI: 10.1007/s11095-013-1231-0. View

van Heesbeen H, Smidt M . Entanglement of Genetics and Epigenetics in Parkinson's Disease. Front Neurosci. 2019; 13:277. PMC: 6449477. DOI: 10.3389/fnins.2019.00277. View

Perluigi M, Sultana R, Cenini G, Di Domenico F, Memo M, Pierce W . Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in Alzheimer's disease: Role of lipid peroxidation in Alzheimer's disease pathogenesis. Proteomics Clin Appl. 2010; 3(6):682-693. PMC: 2843938. DOI: 10.1002/prca.200800161. View

Shen L, Ciesielski M, Ramakrishnan S, Miles K, Ellis L, Sotomayor P . Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS One. 2012; 7(1):e30815. PMC: 3267747. DOI: 10.1371/journal.pone.0030815. View

Sun Y, Li D, Su Y, Zhao H, Pang W, Zhao W . Protective effect of hydrogen sulfide is mediated by negative regulation of epigenetic histone acetylation in Parkinson's disease. Arch Med Sci. 2023; 19(4):1124-1135. PMC: 10408026. DOI: 10.5114/aoms.2020.93121. View

Cao P, Liang Y, Gao X, Zhao M, Liang G . Administration of MS-275 improves cognitive performance and reduces cell death following traumatic brain injury in rats. CNS Neurosci Ther. 2013; 19(5):337-45. PMC: 6493506. DOI: 10.1111/cns.12082. View

Xu W, Parmigiani R, Marks P . Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007; 26(37):5541-52. DOI: 10.1038/sj.onc.1210620. View

10.

Dutta M, Biswas U, Chakraborty R, Banerjee P, Raychaudhuri U, Kumar A . Evaluation of plasma H2S levels and H2S synthesis in streptozotocin induced Type-2 diabetes-an experimental study based on Swietenia macrophylla seeds. Asian Pac J Trop Biomed. 2014; 4(Suppl 1):S483-7. PMC: 4025317. DOI: 10.12980/APJTB.4.201414B58. View

11.

Zhang X, Yang R, Hu B, Lu P, Zhou L, He Z . Reduced Circulating Levels of miR-433 and miR-133b Are Potential Biomarkers for Parkinson's Disease. Front Cell Neurosci. 2017; 11:170. PMC: 5481393. DOI: 10.3389/fncel.2017.00170. View

12.

Chakravarty S, Reddy B, Sudhakar S, Saxena S, Das T, Meghah V . Chronic unpredictable stress (CUS)-induced anxiety and related mood disorders in a zebrafish model: altered brain proteome profile implicates mitochondrial dysfunction. PLoS One. 2013; 8(5):e63302. PMC: 3653931. DOI: 10.1371/journal.pone.0063302. View

13.

Zhu Y, Zhang J, Zeng Y . Overview of tyrosine hydroxylase in Parkinson's disease. CNS Neurol Disord Drug Targets. 2012; 11(4):350-8. DOI: 10.2174/187152712800792901. View

14.

Minones-Moyano E, Porta S, Escaramis G, Rabionet R, Iraola S, Kagerbauer B . MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum Mol Genet. 2011; 20(15):3067-78. DOI: 10.1093/hmg/ddr210. View

15.

Seto E, Yoshida M . Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb Perspect Biol. 2014; 6(4):a018713. PMC: 3970420. DOI: 10.1101/cshperspect.a018713. View

16.

Qiu L, Zhang W, Tan E, Zeng L . Deciphering the function and regulation of microRNAs in Alzheimer's disease and Parkinson's disease. ACS Chem Neurosci. 2014; 5(10):884-94. DOI: 10.1021/cn500149w. View

17.

Suzuki T, Ando T, Tsuchiya K, Fukazawa N, Saito A, Mariko Y . Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J Med Chem. 1999; 42(15):3001-3. DOI: 10.1021/jm980565u. View

18.

Harrison I, Dexter D . Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?. Pharmacol Ther. 2013; 140(1):34-52. DOI: 10.1016/j.pharmthera.2013.05.010. View

19.

Kazantsev A, Thompson L . Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov. 2008; 7(10):854-68. DOI: 10.1038/nrd2681. View

20.

Pringsheim T, Jette N, Frolkis A, Steeves T . The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord. 2014; 29(13):1583-90. DOI: 10.1002/mds.25945. View